Sandra Milligan

Insider Reports History

Location
San Diego, CA
Signature
/s/ Jeff Boerneke, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Sandra Milligan:

Form 4 holding Head of Research & Development

Organon & Co.

Security class
Common Stock
Shares / value
28,599
Estimated value
$615,736
Report date
04 May 2023
Price
$21.53
Ownership
Direct
Form 4 holding Head of Research & Development

Organon & Co.

Security class
Restricted Stock Units
Shares / value
4,984
Estimated value
$107,306
Report date
04 May 2023
Price
$21.53
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Interim CEO

Aspira Women's Health Inc.

Security class
Stock option (right to buy)
Shares / value
25,000
Estimated value
$96,000
Report date
12 Nov 2024
Price
$3.20
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Interim CEO

Aspira Women's Health Inc.

Security class
Restricted Stock Units
Shares / value
0
Estimated value
$0
Report date
31 Dec 2024
Price
$2.42
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Gossamer Bio, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
115,000
Estimated value
Report date
25 Jun 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Sandra Milligan

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .